CTSNet To Go Podcast Episode: Improving Survival in Early Stage NSCLC by Incorporating a 14 Gene Molecular Risk Diagnostic Assay

David Jablons moderated this live event, originally recorded on Nov. 18, 2020, which presented data about the development of a molecular assay based on resected tumor RNA expression from simple paraffin-fixed tissue samples. This is integrated into an algorithm that can assign a risk score for recurrence. This molecular risk score is fully independent of standard TNM staging and does not rely on any other clinical parameters. The assay has been widely validated in thousands of patients and demonstrates both significant prognostic information and the predictive benefit of adjuvant platinum based chemotherapy in high risk patients, as identified by this assay.